X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted Return on Capital Employed of 43.17% for Q4 2025, up 51.61% on a QoQ basis from 89.21% in Q3 2025, and down 1505.0% year-over-year from 3.07% in Q4 2024.
X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 43.17% for Q4 2025.
- Quarterly Return on Capital Employed fell 1505.0% year-over-year to 43.17% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 43.17% (down 1505.0% YoY) and the FY2025 annual result came in at 45.09%, down 1315.0% from the prior year.
- Return on Capital Employed was 43.17% for Q4 2025 at X4 Pharmaceuticals, up from 89.21% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 7.61% in Q1 2025 and bottomed at 132.92% in Q3 2022.
- A 5-year average of 70.72% and a median of 78.16% in 2022 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 10117 bps in 2025, while the deepest fall reached 9779 bps in 2025.
- X4 Pharmaceuticals' Return on Capital Employed stood at 81.19% in 2021, then grew by 4 bps to 78.07% in 2022, then retreated by 0 bps to 78.25% in 2023, then soared by 64 bps to 28.12% in 2024, then tumbled by 54 bps to 43.17% in 2025.
- Business Quant data shows XFOR's Return on Capital Employed at 43.17% in Q4 2025, 89.21% in Q3 2025, and 111.82% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -43.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -43.17% |
| Sep 30, 2025 | -89.21% |
| Jun 30, 2025 | -111.82% |
| Mar 31, 2025 | -7.61% |
| Dec 31, 2024 | -28.12% |
| Sep 30, 2024 | -15.68% |
| Jun 30, 2024 | -14.04% |
| Mar 31, 2024 | -108.79% |
| Dec 31, 2023 | -78.25% |
| Sep 30, 2023 | -72.95% |
| Jun 30, 2023 | -79.62% |
| Mar 31, 2023 | -79.33% |
| Dec 31, 2022 | -78.07% |
| Sep 30, 2022 | -132.92% |
| Jun 30, 2022 | -131.75% |
| Mar 31, 2022 | -94.66% |
| Dec 31, 2021 | -81.19% |
| Sep 30, 2021 | -62.54% |
| Jun 30, 2021 | -51.78% |
| Mar 31, 2021 | -52.82% |